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Group A Streptococcus (GAS) infection causes a range of diseases, but vaccine development
is hampered by the high number of serotypes. Here, using reverse vaccinology the authors
identify SPy_2191 as a cross-protective vaccine candidate. From 18 initially identiﬁed surface
proteins, only SPy_2191 is conserved, surface-exposed and inhibits both GAS adhesion and
invasion. SPy_2191 immunization in mice generates bactericidal antibodies resulting in
opsonophagocytic killing of prevalent and invasive GAS serotypes of different geographical
regions, including M1 and M49 (India), M3.1 (Israel), M1 (UK) and M1 (USA). Resident
splenocytes show higher interferon-γ and tumor necrosis factor-α secretion upon antigen restimulation, suggesting activation of cell-mediated immunity. SPy_2191 immunization signiﬁcantly reduces streptococcal load in the organs and confers ~76-92% protection upon
challenge with invasive GAS serotypes. Further, it signiﬁcantly suppresses GAS pharyngeal
colonization in mice mucosal infection model. Our ﬁndings suggest that SPy_2191 can act as a
universal vaccine candidate against GAS infections.
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treptococcus pyogenes or GAS is a human pathogenic
bacterium. It causes a range of suppurative diseases
(pharyngitis, impetigo), invasive diseases [necrotizing fasciitis, streptococcal toxic shock syndrome (STSS)] and poststreptococcal sequel [Acute rheumatic fever (ARF), rheumatic
heart disease (RHD), glomerulonephritis]. Annually, GAS causes
616 million cases of pharyngitis, 18.1 million severe cases and
517,000 deaths worldwide1. GAS is ninth leading infectious
bacteria in the estimate of mortality and falls with measles,
Haemophilus inﬂuenza type b and hepatitis B. Further, GAS
causes high morbidity and mortality mostly in low and middleincome countries. GAS pathogenicity is underestimated due to
lack of data from developing countries (South-Asian and SubSaharan African countries).
The M protein of GAS is a surface-exposed protein with a
highly variable N-terminal region that forms the basis of different
serotyping in GAS2. More than 220 serotypes of GAS are prevalent in different geographical regions3. Prevalence of a serotype
also changes in few years with time in different regions4,5. The M
protein is a major virulence factor of GAS that helps in adhesion
and invasion of bacteria to epithelial cells and also in evading the
host innate immune response due to its anti-phagocytic function6–8. Few vaccine preparations like 26-valent, 30-valent and J8
were made based on the M-protein, are currently in phase I or II
clinical trials. Additionally, various other subunit vaccines like
C5a peptidase, GAS carbohydrate and serum opacity factor, have
also shown promising results, however no clinical trials were
conducted related to these preparations9–14. The progress in
development of an effective vaccine against GAS is further
impeded due to serotype diversity in different geographical areas,
antigenic variation within serotype and cross-reacting antibodies
causing auto-immune disorders like ARF and RHD2,3,15,16.
Currently, antibiotics like penicillin and cephalosporins among
others are in use to combat various GAS diseases. However,
antibiotic resistance developed by some GAS clinical isolates
against macrolides and tetracyclines in various geographical
regions, has led to a worldwide concern17. Till date, regardless of
a high demand globally, no vaccine has been licensed against GAS
infections.
Genome sequences of various pathogenic bacteria and viruses
are available for the past two decades and have been exploited
immensely in vaccine development. One approach, which was
found to be highly successful to identify universally applicable
vaccine candidates, is reverse vaccinology. It was ﬁrst tested on
serogroup B meningococcus18. Reverse vaccinology coupled with
comparative genomics, proteomics, and bioinformatics allow
reducing the number of pre-clinical candidates to be analyzed for
immunogenicity19–21. It has been established that a successful
vaccine candidate must be conserved, immunogenic, either surface exposed or secretory and should be well expressed22.
Importantly, universal vaccine candidates must protect against
serotypes prevalent in different geographical areas. Based on
reverse vaccinology approach, we predicted a total of 147 genes as
universal GAS vaccine candidates. We further validated the in
silico analysis by exploring the distribution proﬁle of these predicted genes in non-sequenced Indian GAS strains. Among these,
52 genes were present in all the prevalent GAS serotypes of
Indian origin21. In the current study, the available 45 recombinant sera previously generated against these 52 and the other
reported genes20,21 are screened for their role in adherence and
invasion. Among those that are found to be involved in adherence
are subsequently checked for their exposure from the surface of
GAS serotypes of Indian origin. Only one candidate, SPy_2191
tests as a potential vaccine candidate in the mouse model against
ﬁve prevalent and invasive GAS serotypes from India, Israel, UK
and USA. Importantly, this ﬁnding highlights SPy_2191 as a
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promising universal vaccine candidate, in providing signiﬁcant
protection against the globally prevalent and invasive GAS serotypes in different geographical areas.
Results
Inhibition of adherence and invasion. For effective vaccination,
the potential vaccine candidate must be surface exposed, involved
in invasion and adherence23–26. Out of 52 previously predicted
vaccine candidates, 45 sets of immune and preimmune mouse
antisera, generated against recombinant surface/secretory proteins of GAS (Supplementary Table 1)20,21 were used to investigate whether the corresponding surface/secretory proteins had
any role in adherence or invasion. Initially, GAS serotype M49
that caused outbreaks in India and USA was used for this study as
this serotype was found to be most invasive27,28. We found that
18 out of 45 antisera inhibited GAS adhesion by ≥75%; however,
only seven antisera abolished invasion by ≥80% (Table 1). We
found SPy_2191 antisera inhibited adherence and invasion by 89
and 93%, respectively (Table 1). Preimmunized mice antisera for
each recombinant GAS protein were used as a control.
Selection of surface-exposed antigen. One of the criteria for
effective vaccination against any pathogen involves surface
exposure of an antigen and its accessibility by speciﬁc hostgenerated antibodies29. To narrow down our focus in subsequent
studies on the development of a broad-range GAS vaccine, we
employed all the 18 antisera (inhibiting adhesion) to conﬁrm the
exposure of their respective target antigen on Indian GAS M49
cell surface using ﬂow cytometry analysis. Data were analyzed
using the mean ﬂuorescence intensity (MFI) obtained in both
immunized and preimmunized antisera. Candidates showing
>2.4-fold increase in MFI as compared to preimmune controls
were considered signiﬁcantly surface exposed (Fig. 1a). Out of 18
protein candidates, 10 were found to be signiﬁcantly exposed on
GAS cell surface (Fig. 1a, Table 1).
In silico analysis and selection of SPy_2191. Out of the 10
potential surface-exposed GAS vaccine candidates, nine did not
show signiﬁcant inhibition of invasion and therefore were not
considered for further experiments (Table 1). Only SPy_2191showed signiﬁcant inhibition of both adhesion and invasion.
Additionally, in overlay diagram, GAS M49 incubated with
SPy_2191-immunized antisera had signiﬁcantly higher MFI in
comparison to GAS alone and GAS M49 incubated with preimmune antisera (Fig. 1b), suggesting SPy_2191 is surface
exposed. Therefore SPy_2191 was selected for subsequent studies.
Our BLAST analysis revealed that the SPy_2191 coding sequence
was highly conserved across various GAS serotypes of developed
and developing countries, with >98% similarity in all the GAS
genome sequences available in the NCBI database.
SPy_2191 elicit a humoral immune response. The SPy_2191
antigen was expressed in E. coli BL21 (DE3) cells as His6-tagged
recombinant protein and puriﬁed to >95% purity by Ni-NTA
afﬁnity chromatography (Supplementary Figs. 1–4). Mice
immunization was performed as illustrated in Fig. 2a. The
SPy_2191-speciﬁc serum IgG titres were measured at day 14 after
priming, followed by booster immunizations (day 28 and 42) by
indirect ELISA (Fig. 2b). Compared to primary immunization,
the total serum IgG endpoint titers after the 1st and 2nd booster
immunizations were found to be ~3.5 and ~5-fold higher,
respectively (p < 0.0001) (Fig. 2b). Our data related to high IgG
titres (induced by SPy_2191 vaccination) suggested a resilient
humoral immune response.
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Table 1 Neutralization assay showing inhibition of GAS M49 adherence and invasion to HEp-2 cells.
NCBI reference no

Protein annotation

% adhesion inhibition

% invasion inhibition

aNP_268656

cABC

aNP_268747

cABC

77.6
81.4
75.3
99.8
79.8
78
75.8
77.8
91.7
89

19.1
29.0
40.8
36.1
0.95
24.0
65.7
89.9
95
93

96
99.6
88.3
89.2
86
97
78.9
99.7

96.9
73.3
99.7
23.1
84.6
36.9
15.7
86.4

transporter substrate-binding protein
transporter metal binding protein (lipoprotein)
cSurface lipoprotein
cLaminin adhesion
cExtracellular hyaluronate lyase
cEsterase
cStreptokinase A/ Streptokinase A precursor
bATP-binding cassette transporter-like protein
bFoldase PrsA
Hypothetical protein SPy_2191/Transglycosylase SLT domain family
protein
bHypothetical protein SPy_0836
cHypothetical protein SPy_0843
bDipeptidase
cSerine protease
bHypothetical protein SPy_1492
bcAMP factor
bABC transporter lipoprotein
bAcid phosphatase/ phosphotransferase

aNP_269961
aNP_269968
aNP_269203

NP_269743
aNP_269944

NP_269981
aNP_269984
aNP_270099

(This study)

NP_269045
NP_269051
aNP_270005
aNP_270119
aNP_269570
aNP_269402
aNP_268542
aNP_269268

For this purpose 18 antisera generated against surface proteins were selected.
aRepresent protein candidates showing high relative expression in M49/IND as compared to M1/IND GAS.
bOut of these 18, eight candidates were rejected as they were not found to be surface exposed (Fig. 1).
cFrom the remaining 10 candidates, nine candidates, though found to be involved in adherence as well as surface exposed but not showed signiﬁcant inhibition in invasion therefore were not selected.
Only one candidate i.e., NP_270099 showed inhibition in adherence and invasion as well as found to be surface exposed (Fig. 1), therefore was selected for further study. Bold numbers: More than 75%
inhibition in adherence and invasion.

a

b
NP_269268
Cell number

NP_268542
NP_269402
NP_269570
NP_270119
NP_269051
GAS antigens

NP_269045
Fluorescence intensity

NP_270099
NP_269984
NP_269981
NP_269743
NP_269203
NP_269968
NP_269961
NP_268747
NP_268656
NP_270005
NP_269944
0

1

2

3

4

5

Fold difference in mean fluorescence intensity

Fig. 1 Surface localization of potential vaccine candidates on GAS M49 surface. a Surface exposure analysis of 18 selected candidates. GAS M49 cells
were incubated with protein-speciﬁc polyclonal antibodies and surface localization was analyzed by ﬂow cytometry using FITC-conjugated secondary goat
anti-mouse IgG. Mean ﬂuorescence intensity (MFI) obtained for each immunized serum (I) was normalized with the MFI of preimmunized sera (PI)
to measure the fold difference. Serum candidates showing >2.4-fold difference in MFI (represented by red dotted line) were considered signiﬁcant.
b Histogram depicting SPy_2191 surface exposure. In the overlay diagram, purple line represents control M49 GAS cells without antisera, blue line
represents cells with preimmunized antisera and red line represents cells incubated with SPy_2191 antisera. Experiment was repeated two times and data
shown here are a representative experiment.

SPy_2191 -speciﬁc serum antibodies mediate GAS opsonophagocytic killing. Conservation of SPy_2191 sequences across
different GAS serotypes led us to hypothesize that SPy_2191
could trigger protective immunity in a serotype-independent

manner. Hence, to ascertain the biological activity of the
SPy_2191 -speciﬁc IgG antibodies, sera was tested for complement mediated opsonophagocytic killing of different GAS
serotypes by whole blood bactericidal assay. For this purpose,
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Fig. 2 SPy_2191 induces humoral immune response. a Immunization schedule in C57BL/6 mice. b SPy_2191 speciﬁc total IgG endpoint titres in sera
samples (n = 6 mice) collected 2 weeks after priming (day 14) and booster immunizations (day 28 and 42), was measured by Indirect ELISA. One-way
ANOVA followed by Tukey’s multiple-comparison test was employed for calculating the signiﬁcant difference. Data are presented as mean values ± SEM c
Opsonophagocytic activity of SPy_2191 speciﬁc antibodies containing sera (n = 4), was evaluated for bactericidal assay, against various GAS serotypes, viz.
M1/IND, M49/IND, M3.1/IL, M1/USA, and M1/UK. Percent reduction of CFU by SPy_2191-immunized sera was estimated in comparison to PBSimmunized mice sera, used as control. Data are presented as mean values ± SEM. ****P < 0.0001.

PBS-immunized mice sera were used as control. Importantly, all
the tested GAS serotypes (used in this study) were found to be
prevalent, caused invasive diseases in various geographical
areas like USA, Australia, New Zealand, and UK in the past
decade27,30–33. Remarkably, in the presence of SPy_2191 -speciﬁc
antibodies the mean reduction in CFUs of different GAS serotypes was observed between 70 and 90 %, with highest reduction
was found in case of M49/IND (~90 %) followed by M1/IND
(~84 %) and M1/USA (~77 %) (Fig. 2c). Likewise, in case of
M3.1/IL and M1/UK GAS serotypes, ~75 and 71 % reduction in
CFUs were observed (Fig. 2c).
SPy_2191 evoked Th1-baised immune response. To monitor the
efﬁcacy of SPy_2191 vaccination on the development of helper T
cell, the memory-recall response of ex vivo cultured splenocytes
was assessed by measuring the level of different cytokines released
in the culture supernatant after antigen stimulation. Two weeks
after the ﬁnal booster (day 42), mice were euthanized; splenocytes
were isolated and stimulated with SPy_2191 antigen for 72 h.
Overall, a superior cytokine response was observed in SPy_2191vaccinated mice as compared to PBS-immunized mice, which
produced low amount of cytokines upon antigen-stimulation
(Fig. 3). Among all the analysed cytokines, Th1-speciﬁc IFN-γ
and TNF-α level were found to be ~27- and ~15-fold higher in
case of SPy_2191-vaccinated mice as compared to PBS-treated
4

mice (Fig. 3a, b). In case of IL-2 no signiﬁcant difference was
observed between both the groups (Fig. 3c). In contrast to the
strong Th1 response, Th2-speciﬁc IL-6 levels were found to be
~7.5-fold signiﬁcantly higher in the culture supernatant of
SPy_2191-vaccinated mice as compared to PBS-treated mice
(Fig. 3d). However, the levels of IL-4 and IL-10 cytokine levels
were found to be statistically insigniﬁcant under similar condition
(Fig. 3e, f). Additionally, stimulation with SPy_2191 antigen
triggered a robust secretion of Th17-speciﬁc proinﬂammatory
cytokine like IL-17A (P < 0.001; Fig. 3g).
In situ protection and expanded serotype coverage by
SPy_2191 vaccination. We further assessed protective efﬁcacy of
SPy_2191 upon challenge with GAS serotypes from different
geographical areas. Two weeks after the ﬁnal booster, SPy_2191
and PBS vaccinated mice were challenged intraperitoneally with
the LD50 dose of different GAS serotypes (Supplementary
Table 2). Four days post-challenge, mice were sacriﬁced aseptically and the total bacillary load in the liver, lungs, spleen, and
skin was enumerated. Remarkably, in case of all the serotypes, a
signiﬁcant decrease i.e., ~3–5 Log10 GAS CFU load was observed
in all the organs of SPy_2191-immunized mice as compared to
the PBS-treated mice (p < 0.01). This decrease in total bacillary
load in case of each organ was found to be >99% (Fig. 4a–e).
Direct protection to streptococcal infection and extended GAS
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Fig. 3 Th1-baised antigen recall response by SPy_2191-immunized mice splenocytes. Two weeks after the ﬁnal immunization, splenocytes were extracted
(n = 5), cultured under ex vivo conditions and stimulated with SPy_2191 antigen for 72 h. a–g Release of Th1-speciﬁc IFN-γ, TNF-α, and IL-2; Th2-speciﬁc
IL-4, IL-6, and IL-10, and Th17-speciﬁc IL-17A cytokines, was measured in the extracellular culture supernatant. Two-tailed unpaired t-test was employed
for calculating the signiﬁcant difference in all the cases. Data are presented as mean values ± SEM. ****P < 0.0001.

serotype coverage in parallel to the ﬁndings of opsonophagocytic
killing assays; reafﬁrm the potential of SPy_2191 as a vaccine
candidate against GAS infection.
GAS being the most common cause of bacterial pharyngitis, we
further monitored the efﬁcacy of SPy_2191 vaccination in
preventing a mucosal infection. For pharyngeal colonization,
GAS M9 serotype (UK) was used. For this purpose, viable counts
were enumerated on day 5 post nasal infection. Interestingly, the
SPy_2191-vaccinated mice showed (~19 folds) signiﬁcantly lower
CFUs in nasopharynx as compared to PBS-treated mice (Fig. 4f;
p < 0.01).

SPy_2191 provides cross-serotype protection against GAS
infection. Further, we have tested if SPy_2191 vaccination could
increase the survival efﬁcacy of mice challenged with GAS serotypes of different geographical regions. We observed that all the
PBS-treated mice succumbed to death within 8 days post-challenge, regardless of the GAS serotype (Fig. 5). Most importantly,
SPy_2191 was found to be signiﬁcantly protective with ~92, ~86,
~86, ~81, and ~76 % mice survival after challenge with M3.1/IL,
M1/IND, M1/USA, M49/IND, and M1/UK GAS serotypes,
respectively (p < 0.001) (Fig. 5). As SPy_2191 triggered a crossserotype immunity, it could be employed as a universal GAS
vaccine candidate, protecting against prevalent and invasive serotypes from different geographical areas.

Discussion
GAS causes high mortality and morbidity in developing countries
as compared to developed countries34. In addition to their heterogenic serotype distribution worldwide, GAS has an array of
virulence factors, which can evade or inhibit human immune
system making it difﬁcult to design a universal vaccine against all
serotypes. Surface/secretory proteins were suggested as compelling vaccine candidates19,29. The surface-exposed M-protein of
GAS has been identiﬁed as a prominent virulence factor7 primarily due to its crucial role in adhesion to the host cell surface35.
Therefore, M-protein-based vaccine preparation has been well
established. The 30-valent vaccine was shown to evoke bactericidal antibodies against 30 vaccine serotypes and also against 24
of 40 tested non-vaccine serotypes of GAS, suggesting that its
protective efﬁcacy would be better than predicted10. Further, it
has been reported that 26-valent M protein-based vaccine would
cover more serotype diversity in developed countries but its
coverage would be very less in severely affected areas and technologically less advance countries like Sub-Saharan African
countries and Paciﬁc region36. However, due to the emergence of
new emm types, it has been suggested that M-protein-based
multivalent vaccine should also be tested against serotypes of
high-income as well as low- and moderate-income countries.
Therefore, this preparation may not be effective against many
unknown GAS serotypes37. Henceforth, there is an urgent need to
identify a universal vaccine candidate against GAS infections.
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Fig. 4 SPy_2191 immunization reduced organ load post-challenge with different GAS serotypes. Two weeks after the ﬁnal booster immunization with
SPy_2191, C57BL/6 mice were challenged intraperitoneally with different GAS serotypes. Four days post-challenge, three mice from both SPy_2191immunized and placebo groups were sacriﬁced, and the bacterial load (represented as Log10 CFU) was enumerated in the liver, lungs, spleen and skin.
a–d and e represents data of different organ load after challenge with M49/IND, M1/IND, M3.1/IL, M1/USA, and M1/UK serotypes, respectively. Red bar
represents CFUs obtained from PBS control mice and blue bar represents CFUs obtained from SPy_2191-immunized mice. In case of all the organs, across
all the infected serotypes, SPy_2191 effectively reduced the bacterial load compared to the placebo group (minimum signiﬁcance p < 0.01). f The
nasopharyngeal streptococcal load in SPy_2191 and PBS-immunized mice (n = 6), 5 days post-intranasal challenge with GAS M9/UK (**P < 0.01). Data are
presented as mean values ± SEM. The level of signiﬁcance was checked by using two-tailed unpaired t-test.
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Fig. 5 SPy_2191 immunization provided cross-serotype protection against GAS. Survival of mice (n = 12) from each group infected with different GAS
serotypes, was monitored for death until 10 days. The results are presented as percent survival. To calculate the signiﬁcance of difference in survival
studies, the log-rank test (Mantel-Cox) was applied. ***P < 0.001; ****P < 0.0001. Survival curves were generated from two independent experiments.

Identiﬁcation and characterization of GAS vaccine candidates
have been reported earlier also. In the past, high throughput
strategies have been used to identify antigens that are immunogenic during GAS infection. Similarly, proteomic analyses of
surface-associated proteins have been employed to map for suitable GAS vaccine candidates20. In the latter studies, interpretations have been drawn either based on antigen’s immunogenicity
index or on its cell surface-exposure. In order to identify a universal vaccine candidate, we have undertaken a very robust three
point criteria for selection, viz. (1) candidate should be surface
exposed and conserved across prevalent and disease causing GAS
serotypes of developed as well as developing countries (2)
involved in both GAS adhesion as well as invasion (3) should be
immunogenic in nature to induce adaptive immune response in
host. Based on these criteria and stringent screening, we found
that SPy_2191 was the only surface-exposed required for both
GAS adhesion as well as invasion (Table 1 and Fig. 1). Further,
the presence and conservativeness of SPy_2191 was checked in all
the available sequenced genomes of GAS. We found that it was
98% conserved in all available GAS genomes. On the basis of its
conserved nature, we speculate that SPy_2191 might be essential
for viability or persistence of most of the GAS serotypes circulation in human population. Additionally, we found that it
induces good immunity and provides good protection in mice.
Therefore present study conclusively deﬁnes a robust and
improved approach to identify and validate one of the best possible universal vaccine candidates.
SPy_2191 was ﬁrst reported in a genome-wide study and found
to be expressed more during phagocytosis38. The 204 amino acid
residue protein harboured a 41-mer signal peptide and was predicted to be transported by the Sec translocon and cleaved by
signal peptidase I (SignalP-5.0). Further, the conserved domain
prediction tool of NCBI suggests SPy_2191 to be an apparent
member of the Lyz-like superfamily with a lytic transglycosylase
domain and two membrane-spanning segments, similar to that of
soluble lytic transglycosylases (SLT), which catalyze the cleavage
of the β-1,4-glycosidic bond between N-acetylmuramic acid
(MurNAc) and N-acetyl-D-glucosamine (GlcNAc). Although, at
this stage the above stated functionality of SPy_2191 is only
speculative and requires further biochemical characterization.
To test whether the SPy_2191 could induce an immune
response in mice, after the second and third immunization,
antisera were analyzed to check whether antibodies were generated against SPy_2191. We found that SPy_2191 is capable of

inducing humoral adaptive immune responses as we observed
signiﬁcantly high IgG antibody endpoint titer after second and
third immunization in comparison to ﬁrst immunization
(Fig. 2b). Five prevalent and invasive GAS serotypes of Israel, UK,
USA, and India were tested for bactericidal assay to validate the
functionality of the SPy_2191-induced humoral immunity. The
average killing was observed against all tested serotypes, which
range between 71–90% (Fig. 2c). Our data suggest that antibodies
present in sera were able to opsonize and kill all the GAS serotypes successfully.
It is known that cytokines are the effector molecules that
control and determine the type of adaptive immune response
generated within a host, upon encountering any pathogen39. Restimulation of SPy_2191-vaccinated mice splenocytes with the
antigen showed higher secretion of Th1-type IFN-γ and TNF-α
cytokines, signifying the activation of cell-mediated adaptive
immunity (Fig. 3a). TNF-α is known to instigate the NF-κB
pathway which involved induction in the synthesis of other innate
cytokines like IL-10 and IL-640. In our study also, a signiﬁcant
increase in Th2-type IL-6 cytokine was observed upon SPy_2191
vaccination. Similarly, upon antigen recall, the subsequent
increase in the secretion of proinﬂammatory cytokine-IL-17A,
could be another salient arsenal of SPy_2191 immune response in
increasing the protective efﬁcacy against GAS serotypes (Fig. 5).
The pivotal role of IFN-γ and IL-17A cytokines in protection and
clearance of invasive GAS infections is well documented10,41–44.
Indeed, IFN-γ at the infection site is thought to be critical
for protection and it further triggers the activation and functioning of myeloid cells including polymorphonuclear leukocytes
(PMNs), which play a key role in survival from GAS infections41.
Altogether, we suggest that higher production of Th1-speciﬁc
IFN-γ and TNF-α, and Th17-speciﬁc IL-17A cytokines by
splenocytes in case of SPy_2191-vaccinated mice after antigen
re-stimulation mimics its potentiality for a memory-recall
responses against GAS infections and validates immunomodulatory competency. Whether it is mediated by CD8+ cytotoxic T
lymphocytes and CD4+ Th1 lymphocytes is not studied in
the present study45, therefore, needs warrant investigation.
Importantly, SPy_2191 was found to evoke both humoral as
well as cell-mediated adaptive immune responses in mice
(Figs. 2b, c, 3a, b).
Multi-organ failure during GAS infections (STSS and sepsis)
can be correlated with the bacterial burden of peripheral organs.
Therefore, we have also investigated whether vaccination with
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Fig. 6 Adhesion and invasion of GAS in placebo and SPy_2191-vaccinated mice. a Graphical representation of how GAS infects a host by ﬁrst adhering
then colonizing on the host cell surface, later invades and disseminates inside the cell. b In SPy_2191-vaccinated mice, GAS infection was bypassed
plausibly due to the presence of bactericidal antibodies that caused opsonophagocytosis, thus blocking adhesion of bacteria on the host cell surface and
subsequently hindered colonization and invasion of GAS within the host. Further a Th1-biased immune response and immuno-stimulation triggered by
SPy_2191 helps the mice to survive against GAS challenge’.

SPy_2191 can reduce bacterial load in different organs of mice.
We found that application of SPy_2191 led to enhanced bacterial
clearance in lungs, liver, spleen and skin of mice upon challenge
with different GAS serotypes (Fig. 4a–e). It is important to note
that GAS causes ~600 million new cases of pharyngitis each year1.
It has been reported that pharyngeal infection not only causes
acute illness but also can trigger the postinfectious syndromes of
poststreptococcal glomerulonephritis and acute rheumatic
fever46. Although rheumatic fever was found to be uncommon in
most developed countries, however, it is a leading cause of
acquired heart disease in the school going children in case of
many economically less developed countries like sub-Saharan
Africa, India, etc1. Therefore, we have also used nasopharyngeal
infection model to test SPy-2191 as a vaccine candidate. Interestingly, SPy_2191 vaccination signiﬁcantly reduced GAS nasopharyngeal load upon intranasal challenge (Fig. 4f). We suggest
that SPy_2191 can also be used as a vaccine candidate in case of
pharyngeal infection. However, further investigations are
required to determine the immunomodulatory mechanism of
SPy_2191 induced protection against pharyngitis. The efﬁcacy of
a vaccine candidate is judged mainly by the degree of protection it
provides to the recipient. Ability of SPy_2191 to modulate protective efﬁcacy can be observed at different levels, starting from
activation of Th1 and Th17-speciﬁc cytokines, generation of a
repertoire of antibodies and reduction of bacterial burden in
different organs of mice. Further, SPy_2191 was tested for in vivo
protection and was found to be immunogenic and protective in
mice against ﬁve prevalent and invasive GAS serotypes belongs to
four different countries (Fig. 5). Ours is the ﬁrst comprehensive
8

report on the vaccine potential of SPy_2191 in modulating host
immune responses.
For the advancement of diseases in the host, bacteria must
adhere, colonize on host surface and invade inside host by subverting host immune system with a range of virulence factors.
Gram-positive bacteria such as Streptococci have evolved with
diverse pathogenic factors works as adhesins to cause diseases.
Therefore, we hypothesize that if we can inhibit adhesion of
bacteria to host cells, then we may be able to bypass bacterial
infection inside host (Fig. 6). Our study reports, SPy_2191 is a
highly conserved, extracellular protein, involved in adhesion and
invasion; protective, elicit bactericidal antibodies, hence, we
conclude that SPy_2191 can act as a universal potential vaccine
candidate against global important human pathogen GAS. This
approach can be used for identiﬁcation of new vaccine candidates
against pathogenic bacteria especially those infect host severely
after invasion like Listeria, Salmonella, and Shigella47.
Methods
Bacterial strains and culture conditions. GAS serotypes M1 and M49 from India
(IND); M3.1 from Israel (IL); M1 from USA; and M1 and M9 (pharyngitis causing
strain) from UK, were used in the present study. Escherichia coli DH5α and BL21
(DE3) strains were used for cloning and expression of recombinant proteins. GAS
and E. coli cultures were grown in Todd Hewitt Broth (THB) and Luria-Bertani
(LB) medium respectively at 37 °C at 220 rpm shaking. For plating and CFU
enumeration of GAS serotypes, 5% sheep blood agar plates were used.

Human cell line and culture conditions. Human epithelial type 2 (HEp-2) cell line
was procured from the National Centre for Cell Science, Pune, India and used for
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neutralization assay. HEp-2 cell line was maintained in RPMI 1640 with 10% fetal
bovine serum (FBS), at 37 °C with 5% CO2.
In vitro neutralization assay. This assay was performed to ﬁnd the role of selected
surface proteins in adherence/invasion of GAS24. Mice were immunized with 45
different surface-exposed/secretory recombinant proteins followed by collection of
antisera20. Polyclonal antibodies present in immunized antisera (gift from GSK
vaccine, Siena, Italy) were incubated with GAS and then introduced on HEp-2 cell
line. Preimmune sera was used as the negative control. Brieﬂy, Indian GAS M49
was grown till OD600 reaches ~0.5. Cells (4 × 107) were collected and diluted in
RPMI 1640 in the ratio of 1:10. Forty microliters of GAS dilution was mixed with
10 µl of mice sera (1:250 dilution in PBS) raised against each recombinant protein
in 2.5 ml RPMI 1640 medium. The mixture was incubated for 1 h at 4 °C and 500 µl
of it was added to conﬂuent HEp-2 cells (80 %) at a multiplicity of infection (GAS/
mammalian cells) of 0.1:1 in a 24 well plate and kept at 37 °C in a 5% CO2
incubator (Shellab, Cornelius, OH, USA) for 2 h. These infected monolayers were
washed thrice with PBS to remove non-adherent GAS. To study invasion, adherent
GAS cells were killed by treating the monolayers with 100 μg ml−1 gentamycin and
5 μg ml−1 penicillin containing complete RPMI 1640 media. The monolayer was
then washed ﬁve times with PBS followed by addition of 0.2 ml of 0.25% trypsinEDTA (Himedia, Mumbai, India) for 5–7 min at 37 °C in a 5% CO2 incubator. To
obtain the internalized GAS load, monolayer was disrupted using 0.8 ml of ice-cold
0.025% Triton X-100 followed by repeated pipetting. Further, this mixture was
diluted accordingly and plated on 5% sheep blood agar plates. The plates were
incubated overnight at 37 °C and GAS CFUs were counted.
To study adherence, all the conditions were kept the same as mentioned above,
except in this case, no antibiotic treatment was given after the ﬁrst 2 h of
incubation. The number of attached GAS was calculated as total CFUs (attached
and invaded) minus invaded CFUs. Each test was done in quadruplicate and the
number of CFUs recovered per plate was determined. Percent inhibition of
adherence was calculated using the formula = [1-mean CFUs in the presence of
immunized serum/mean CFUs in presence of preimmunized mice serum] × 100.
Flow cytometry analysis of surface proteins. Surface exposed proteins were
mapped on the GAS membrane using protein-speciﬁc polyclonal antibodies. In
brief, the GAS M49 serotype was grown in THB to an OD600 ~0.4, centrifuged at
7000 rpm and the resulting pellet was washed with PBS. Five hundred μl of bacterial cells were taken and suspended in 50 μl new-born calf serum. This mixture
was incubated for 20 min at RT. From this, 100 μl of bacterial suspension was
dispensed in fresh microcentrifuge tubes and mixed with 100 μl of preimmune/
immune sera (1:100 dilution in PBS containing 0.1% BSA) and further incubated
for 30 min. Further, cells were washed with washing buffer (0.1% BSA in PBS) and
incubated with goat anti-mouse IgG conjugated with FITC (in PBS containing
0.1% BSA and 20% new-born calf serum) to a ﬁnal dilution of 1:100 for 30 minutes.
Cells were ﬁnally washed, re-suspended in PBS and analyzed with BD FACSCalibur™ ﬂow cytometer using BD CellQuest™ Pro software (Becton Dickinson).
Molecular cloning, expression and puriﬁcation. SPy_2191 was PCR ampliﬁed
using the genomic DNA of M49 GAS as template and gene speciﬁc primers (FP5’CGCGGATCCATGTTTAAGAAAGAAAATTTAAAACAACG3′ and RP-5′
CCGCTCGAGGTAACCCCAAGCTGATAAACCTTG3′), at an annealing temperature of 54.7 °C. Ampliﬁed PCR product was eluted using gel extraction kit
(Agilent Technologies, USA) and cloned in protein expression vector pET-21a
(Novagen) at the BamHI and XhoI sites, followed by transformation into E. coli
DH5α. Positive clones were screened by colony PCR using gene speciﬁc primers
(described above) and conﬁrmed by sequencing (Supplementary Fig. 2).
Plasmid (containing the cloned fragment) was isolated from the positive clones
and transformed into chemically competent E. coli BL21(DE3) cells for SPy_2191
expression. The His6-tagged SPy_2191 was puriﬁed by the Ni-NTA afﬁnity
chromatography. To do this, 500 ml of LB media containing 100 µg ml−1
ampicillin was inoculated with 0.1% of overnight grown culture and grown to
OD600 ~0.6 at 37 °C with 180 rpm shaking. For protein expression, the culture was
induced with 1 mM IPTG and further incubated for 4 h at 37 °C. Cells were
harvested by centrifugation and suspended in extraction buffer A [50 mM TrisHCl, pH 8.0, 300 mM NaCl, 1 mM PMSF (serine protease inhibitor), 1 mg ml−1
lysozyme, 0.05% Triton X-100] and incubated for 30 min at room temperature.
Cells were lysed by sonication (30% amplitude, at 4 °C) on a Sonics VibraCellTM
digital sonicator. The lysate was centrifuged for 20 min at 11,000 × g and subjected
to Ni-NTA afﬁnity chromatography (Qiagen). The His6-tagged SPy_2191 bound to
the column, was washed ﬁrst with buffer B [50 mM Tris-Cl (pH 8.0), 300 mM NaCl
and 5% glycerol] and then by buffer C (buffer B containing 30 mM imidazole).
Further, protein was eluted in Buffer B containing 300 mM imidazole. The eluted
fractions were analysed on SDS–PAGE and concentrated to 5 mg ml−1 by using
Macrosep® Advance Centrifugal Devices (3 kDa cut-off), dialyzed against 1xPBS
pH 7.4 and stored at 4 °C.
Mice immunization. Six weeks old, speciﬁc-pathogen-free, inbred, female C57BL/6
mice were purchased from Hylasco Biotechnology India Pvt. Ltd., housed in a
ventilated animal caging system, fed pelleted diet and water ad libitum. Mice were
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immunized subcutaneously (n = 18) with optimal concentration i.e. 10 μg of
recombinant SPy_2191 (Supplementary Fig. 5) in PBS emulsiﬁed with complete
Freund’s adjuvant (CFA) in the ratio of 1:1. Additionally, mice were administered
two subcutaneous booster doses of SPy_2191 with incomplete Freund’s adjuvant
(1:1) on day 14 and 28. In the placebo group, mice were immunized with CFA/IFA
in emulsiﬁcation with PBS alone. Blood was collected by retro-orbital bleeding on
speciﬁc time intervals (described below), sera was isolated and stored at −80 °C.
Two weeks after the ﬁnal booster, ﬁve mice from each group were euthanized
under anaesthesia by cervical dislocation for splenocyte culturing and cytokine
proﬁling.
Measurement of SPy_2191-speciﬁc antibody titre. To evaluate SPy_2191 antigen’s vaccine potential, total serum IgG levels were measured on day 0 (preimmune), 14, 28, and 42, by indirect enzyme-linked immunosorbent assay
(ELISA). Brieﬂy, 96-well high-binding, polystyrene microtiter plates (NuncMaxiSorp™) were coated with SPy_2191 at a concentration of 500 ng per well, in coating
buffer containing 50 mM sodium bicarbonate (pH 9.6). The plate was incubated
overnight at 4 °C, followed by blocking with 150 μl of 2% bovine serum albumin
(BSA) for 2 h at 37 °C. Serial dilution of the sera was prepared in PBS (102–106)
and 0.1 ml of each dilution was added to the SPy_2191 precoated wells in triplicates
and further incubated for 1 h at 37 °C. The plate was then washed four times with
1×PBST (1×PBS containing 0.05% tween-20) and incubated with horseradish
peroxidase (HRP) conjugated goat anti-mouse IgG at a dilution of 1:5000, in PBS
containing 2% BSA. After washing four times with 1×PBST, the microtiter plate
was incubated in dark with BD OptEIA TMB substrate (BD Bioscience) for 20–30
min. The reaction was stopped by adding 1 N HCl before measuring the absorbance at 450 nm using 570 nm as the reference wavelength, in a TECAN SunriseTM
microplate reader. The endpoint titre was deﬁned as the highest sera dilution that
gave an absorbance > mean+3 SD absorbance obtained at 1:100 dilution of the
only PBS-immunized mice group.
Bactericidal assay. This in vitro assay was used to validate the functionality of
SPy_2191-speciﬁc antibodies in GAS killing. For this purpose, GAS serotypes were
grown at 37 °C to OD600~0.6 in 5 ml THB broth and diluted to 10−5 in sterile
1xPBS. In each case, 50 µl of heat-inactivated serum (1:16 in dilution) was mixed
with diluted GAS and incubated for 20 min at 25 °C. As a source of blood cells and
complement, 400 μl of non-opsonic heparinized donor blood was added to the
mixture and further incubated at 37 °C for 3 h with an end to end rotation. Each
tube was serially diluted and the mixture was plated in duplicate on 5% sheep blood
agar plate. Further, plates were incubated overnight at 37 °C and the resulting
colonies were counted. Percent reduction in CFUs was counted by the formula—
Opsonic activity of serum sample = [1-mean CFUs in the presence of SPy_2191immunized serum/mean CFUs in presence of PBS-immunized mice serum] × 100.
Splenocyte culturing and stimulation. Two weeks after the ﬁnal booster
immunization, ﬁve mice from each group were sacriﬁced and their spleen was
aseptically isolated. The spleen was washed with sterile PBS and crushed between
frosted slides in RPMI 1640 medium containing 10% FBS. To obtain a tissue-free
homogenous cell-suspension, the splenic contents were ﬁltered through a 70 µm
cell strainer. The contaminating red blood cells (RBCs) were lysed using 0.9%
NH4Cl, for 10 min at room temperature. The resulting cell pellet was washed three
times with complete RPMI 1640 medium and cell viability was measured by the
trypan blue (0.4%) staining using a haemocytometer. Subsequently, splenocytes
were seeded at 106 cells per well in a 96-well tissue culture plate in complete RPMI
1640 medium and stimulated with either 10 µg of SPy_2191 antigen in PBS or PBS
alone (0.2 µm ﬁlter-sterilized). Cells were stimulated with concanavalin A as a
positive control. Plates were incubated at 37 °C with 5% CO2 and 95% humidity.
After 72 h of incubation, culture supernatants were collected and stored at −80 °C
until further use.
Cytokine measurements. The BD™ Cytometric Bead Array (CBA) mouse Th1/
Th2/Th17 cytokine kit (BD Biosciences) was used to determine the levels of Th1speciﬁc (IFN-γ, TNF-α, IL-2), Th2-speciﬁc (IL-4, IL-6, IL-10) and Th17-speciﬁc
(IL-17A) cytokines in the splenocyte culture supernatant. All the samples were
processed according to the manufacturer’s instructions. The data was acquired on a
BD FACSCantoTM II ﬂow cytometer (Becton Dickinson) installed at the BD-JH
FACS Academy, Jamia Hamdard, India and analysed using the FCAP ArrayTM
software, V3.0 (Becton Dickinson).
GAS infection and protective efﬁcacy. All the GAS challenge experiments were
carried out within laminar ﬂow safety enclosures in the BSL-3 facility and infected
animals were housed in micro-isolator cages. Mice were challenged intraperitoneally with LD50 of the desired GAS serotypes (1 × 108 CFU per mice in case of
M49/IND, M3.1/IL and M1/USA; and 5 × 107 CFU per mice in case of M1/IND
and M1/UK) in PBS, 2 weeks after the ﬁnal booster. For the next 10 days, mice
were monitored for behavioural changes and survival or death due to GAS
infection. After 10 days, all the remaining mice were euthanized.
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Measurement of bacterial load. For enumeration of GAS load in different organs,
viz. lungs, spleen, liver and skin, three mice from both SPy_2191-immunized and
placebo groups were euthanized under anaesthesia by cervical dislocation. All the
organs were collected aseptically, weighed, washed, and homogenized in 2 ml of
sterile PBS. The resulting homogenate was serially diluted to 10−6 in PBS and the
dilutions were plated in duplicate on 5% sheep blood agar plates. The plates were
incubated overnight at 37 °C and colonies were counted next day.
Intranasal infection. For pharyngeal colonization, SPy_2191-immunized mice
(n = 6) were intranasally infected with pharyngitis causing M9 (H728) strain48.
Brieﬂy, mice were restrained by physical means and 20 µl of droplet containing
~1.2 × 109 CFUs was placed on the nares for inhalation. After 5 days, the nasopharynx was aseptically dissected, weighed and homogenized in sterile PBS. Bacterial burden was monitored by plating the serial dilutions of homogenized nasal
tissue onto 5% sheep blood agar plates.
Ethical statement. Mice infection studies were carried out in strict accordance
with the recommendations given by the Institutional Animal Ethics Committee
(IAEC), Jawaharlal Nehru University and Council for the Purpose of Control and
Supervision of Experiments on Animals (CPCSEA, Ministry of Social Justice and
Empowerment, Government of India), New Delhi. Protocols were approved by
IERB board and all efforts were made to minimize the suffering of mice employed
in the study with IAEC code 10/2017.
Statistics and reproducibility. GraphPad Prision 6 software (La Jolla, CA) was
used for statistical analysis. The GAS challenge experiments were evaluated using
Kaplan–Meier survival estimates and statistically analysed by using Log-rank
(Mantel-Cox) test. For comparisons between multiple groups, one-way analysis of
variance (ANOVA) followed by Tukey’s multiple-comparison test was used. The
level of signiﬁcance in cytokine production and CFU enumeration studies, was
checked by using two-tailed unpaired t-test. All attempts at replication of the data
were successful. All the experiments were replicated and performed independently
at least twice.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.

Data availability
The data that support the ﬁndings of this study are available within the article and its
Supplementary Information ﬁles, or are available from the corresponding author upon
request. Source data are provided with this paper.

Received: 22 December 2018; Accepted: 23 June 2020;

References
1.

Carapetis, J. R., Steer, A. C., Mulholland, E. K. & Weber, M. The global burden
of group A streptococcal diseases. Lancet Infect. Dis. 5, 685–694 (2005).
2. Fischetti, V. A. Streptococcal M protein: molecular design and biological
behavior. Clin. Microbiol Rev. 2, 285–314 (1989).
3. Sanderson-Smith, M. et al. A systematic and functional classiﬁcation of
Streptococcus pyogenes that serves as a new tool for molecular typing and
vaccine development. J. Infect. Dis. 210, 1325–1338 (2014).
4. Chiou, C. S. et al. Association of the shufﬂing of Streptococcus pyogenes clones
and the ﬂuctuation of scarlet fever cases between 2000 and 2006 in central
Taiwan. BMC Microbiol. 9, 1–9 (2009).
5. Shulman, S. T. et al. Seven-year surveillance of North American pediatric
group A streptococcal pharyngitis isolates. Clin. Infect. Dis. 49, 78–84 (2009).
6. Cue, D., Dombek, P. E., Lam, H. & Cleary, P. P. Streptococcus pyogenes
serotype M1 encodes multiple pathways for entry into human epithelial cells.
Infect. Immun. 66, 4593–4601 (1998).
7. Metzgar, D. & Zampolli, A. The M protein of group A streptococcus is a key
virulence factor and a clinically relevant strain identiﬁcation marker. Virulence
2, 402–412 (2011).
8. Siemens, N., Patenge, N., Otto, J., Fiedler, T. & Kreikemeyer, B. Streptococcus
pyogenes M49 plasminogen/plasmin binding facilitates keratinocyte invasion
via integrin-integrin-linked kinase (ILK) pathways and protects from
macrophage killing. J. Biol. Chem. 286, 21612–21622 (2011).
9. McNeil, S. A. et al. Safety and immunogenicity of 26-valent group A
streptococcus vaccine in healthy adult volunteers. Clin. Infect. Dis. 41,
1114–1122 (2005).
10. Dale, J. B., Penfound, T. A., Chiang, E. Y. & Walton, W. J. New 30-valent M
protein-based vaccine evokes cross-opsonic antibodies against non-vaccine
serotypes of group A streptococci. Vaccine 29, 8175–8178 (2011).

10

11. Batzloff, M. R. et al. Protection against group A streptococcus by
immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria
toxoid-speciﬁc antibodies to protection. J. Infect. Dis. 187, 1598–1608 (2003).
12. Cleary, P. P., Matsuka, Y. V., Huynh, T., Lam, H. & Olmsted, S. B.
Immunization with C5a peptidase from either group A or B streptococci
enhances clearance of group a streptococci from intranasally infected mice.
Vaccine 22, 4332–4341 (2004).
13. Sabharwal, H. et al. Group A streptococcus (GAS) carbohydrate as an
immunogen for protection against GAS infection. J. Infect. Dis. 193, 129–135
(2006).
14. Courtney, H. S., Hasty, D. L. & Dale, J. B. Serum opacity factor (SOF) of
Streptococcus pyogenes evokes antibodies that opsonize homologous and
heterologous sof-positive serotypes of group A streptococci. Infect. Immun.
71, 5097–5103 (2003).
15. Lannergård, J. et al. The hypervariable region of Streptococcus pyogenes M
protein escapes antibody attack by antigenic variation and weak
immunogenicity. Cell Host Microbe 10, 147–157 (2011).
16. Massell, B. F., Honikman, L. H. & Amezcua, J. Rheumatic fever following
streptococcal vaccination. JAMA 207, 1115–1119 (1969).
17. Cattoir, V. in Streptococcus Pyogenes: Basic biology to clinical manifestations (eds
Ferretti, J. J., Stevens, D. L. & Fischetti, V.A.) (Oklahoma City, 2016) pp. 1–24.
18. Rappuoli, R. Reverse vaccinology, a genome-based approach to vaccine
development. Vaccine 19, 2688–2691 (2001).
19. Rodríguez-Ortega, M. J. et al. Characterization and identiﬁcation of vaccine
candidate proteins through analysis of the group A streptococcus surface
proteome. Nat. Biotechnol. 24, 191–197 (2006).
20. Bensi, G. et al. Multi high-throughput approach for highly selective
identiﬁcation of vaccine candidates: the group A streptococcus case. Mol. Cell
Proteom. 11, 1–12 (2012).
21. Sharma, A. et al. Identiﬁcation of potential universal vaccine candidates
against group A streptococcus by using high throughput in silico and
proteomics approach. J. Proteome Res. 12, 336–346 (2013).
22. Grandi, G. Bacterial surface proteins and vaccines. F1000 Biol. Rep. 3, 1–3 (2010).
23. Maione, D. et al. Identiﬁcation of a universal group B streptococcus vaccine by
multiple genome screen. Science 309, 148–150 (2005).
24. Johri, A. K. et al. Transcriptional and proteomic proﬁles of group B
streptococcus type V reveal potential adherence proteins associated with highlevel invasion. Infect. Immun. 75, 1473–1483 (2007).
25. Chiang-Ni, C. & Wu, J. J. Effects of streptococcal pyrogenic exotoxin B on
pathogenesis of Streptococcus pyogenes. J. Formos. Med. Assoc. 107, 677–685
(2008).
26. Wahid, R. M. et al. Immune response to a laminin-binding protein (Lmb) in
group A streptococcal infection. Pediatr. Int. 47, 196–202 (2005).
27. Gherardi, G., Vitali, L. A. & Creti, R. Prevalent emm types among invasive
GAS in Europe and north America since year 2000. Front Public Heal 6, 1–11
(2018).
28. Arya, D. K., Sharma, A., Mehta, G., Dua, M. & Johri, A. K. Molecular
epidemiology and virulence characteristics of prevalent group A streptococci
recovered from patients in northern India. J. Infect. Dev. Ctries 8, 271–281
(2014).
29. Pizza, M. et al. Identiﬁcation of vaccine candidates against serogroup B
meningococcus by whole-genome sequencing. Science 287, 1816–1820 (2000).
30. Rudolph, K. et al. Epidemiology of invasive group A streptococcal disease in
Alaska, 2001 to 2013. J. Clin. Microbiol. 54, 134–141 (2016).
31. Nelson, G. E. et al. Epidemiology of invasive group A streptococcal infections
in the United States, 2005–2012. Clin. Infect. Dis. 63, 478–486 (2016).
32. Williamson, D. A. et al. Molecular epidemiology of group A streptococcus
from pharyngeal isolates in Auckland, New Zealand, 2013. N. Z. Med. J. 127,
55–60 (2014).
33. Fritzer, A. et al. Novel conserved group A streptococcal proteins identiﬁed by
the antigenome technology as vaccine candidates for a non-M protein-based
vaccine. Infect. Immun. 78, 4051–4067 (2010).
34. Walker, M. J. et al. Disease manifestations and pathogenic mechanisms of
group A streptococcus. Clin. Microbiol. Rev. 27, 264–301 (2014).
35. Okada, N., Liszewski, M. K., Atkinson, J. P. & Caparon, M. Membrane
cofactor protein (CD46) is a keratinocyte receptor for the M protein of the
group A streptococcus. Proc. Natl Acad. Sci. USA 92, 2489–2493 (1995).
36. Steer, A. C. et al. Status of research and development of vaccines for
Streptococcus pyogenes. Vaccine 34, 2953–2958 (2016).
37. Dale, J. B. et al. Potential coverage of a multivalent M protein-based group A
streptococcal vaccine. Vaccine 31, 1576–1581 (2013).
38. Voyich, J. M. et al. Genome-wide protective response used by group A
Streptococcus to evade destruction by human polymorphonuclear leukocytes.
Proc. Natl Acad. Sci. USA 100, 1996–2001 (2003).
39. Banyer, J. L., Hamilton, N. H., Ramshaw, I. A. & Ramsay, A. J. Cytokines in
innate and adaptive immunity. Rev. Immunogenet. 2, 359–373 (2000).
40. Hayden, M. S. & Ghosh, S. Regulation of NF-κB by TNF family cytokines.
Semin Immunol. 26, 253–266 (2014).

NATURE COMMUNICATIONS | (2020)11:3545 | https://doi.org/10.1038/s41467-020-17299-x | www.nature.com/naturecommunications

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-17299-x

41. Raeder, R. H., Barker-Merrill, L., Lester, T., Boyle, M. D. & Metzgera, D. W. A
pivotal role for interferon-γ in protection against group a streptococcal skin
infection. J. Infect. Dis. 181, 639–645 (2000).
42. Matsumura, T. et al. Interferon-γ-producing immature myeloid cells confer
protection against severe invasive group A Streptococcus infections. Nat
Commun. 3, 1–11 (2012).
43. Gratz, N. et al. Type I interferon production induced by Streptococcus
pyogenes-derived nucleic acids is required for host protection. PLoS Pathog. 7,
e1001345 (2011).
44. Carey, A. J. et al. Interleukin-17A contributes to the control of Streptococcus
pyogenes colonization and inﬂammation of the female genital tract. Sci. Rep. 6,
26836 (2016).
45. Schoenborn, J. R. & Wilson, C. B. Regulation of interferon-γ during innate
and adaptive immune responses. Adv. Immunol. 96, 41–101 (2007).
46. Wessels, M. R. Clinical practice. Streptococcal pharyngitis. N. Engl. J. Med. 17,
648–655 (2011).
47. Pizarro-Cerdá, J. & Cossart, P. Bacterial adhesion and entry into host cells.
Cell 124, 715–727 (2006).
48. Puchta, A., Verschoor, C. P., Thurn, T. & Bowdish, D. M. Characterization of
inﬂammatory responses during intranasal colonization with Streptococcus
pneumoniae. J. Vis. Exp. 17, e50490 (2016).

ARTICLE

written by P.S., M.G., A.K.J., R.B., and E.H. A.K.J., P.S., M.G., and A.S. analyzed the
data. Chemicals were provided by A.K.J., R.B., M.D., and V.Y. Project was supervised by
A.K.J. and R.B.

Competing interests
The authors declares no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467020-17299-x.
Correspondence and requests for materials should be addressed to A.K.J.
Peer review information Nature Communications thanks Mehfuz Zaman and the other,
anonymous, reviewer(s) for their contribution to the peer review of this work. Peer
reviewer reports are available.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.

Acknowledgements
P.S. is thankful to Council of Scientiﬁc and Industrial Research (CSIR), Govt. of India for
providing research fellowship. M.G. is thankful to the University Grants Commission
(UGC), Govt. of India, for providing Dr. D. S. Kothari Postdoctoral fellowship [No. F.42/2006(BSR)/17-18/0044]. A.K.J. and E.H. are thankful to the Indo-Israel project F.No:65/2016 (1 C) funded by UGC, Govt. of India and Israel Science Foundation. We are also
very thankful to Prof. Michael Wessels, Boston children’s hospital, Boston and Prof.
Shiranee Sriskandan, Imperial college, London for providing GAS M1 and M9 serotypes
respectively. We are very grateful to Dr. Rino Rappuoli and Dr. Immaculada, GSK
vaccine, Siena, Italy for providing the recombinant sera, critical reading of the MS that
helped in improving the MS.

Author contributions
Project initiated by A.K.J., E.H., and R.B. P.S., M.G., and V.K.S. have performed the
experiments. P.S., M.G., A.K.J., M.D., and V.Y. have designed the experiments. MS is

Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2020

NATURE COMMUNICATIONS | (2020)11:3545 | https://doi.org/10.1038/s41467-020-17299-x | www.nature.com/naturecommunications

11

